Parallel Advisors, LLC Cellectis S.A. Transaction History

Parallel Advisors, LLC

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 May 20, 2024	BUY	$1.72 - $2.12 $860 - $1,060	500 New	500 $0
Q2 2023 Aug 04, 2023	BUY	$1.72 - $2.12 $860 - $1,060	500 New	500 $0
Q4 2021 Jan 20, 2022	SELL	$8.01 - $12.84 $648 - $1,040	-81 Closed	0 $0
Q2 2021 Aug 06, 2021	SELL	$14.36 - $20.93 $3,733 - $5,441	-260 Reduced 76.25%	81 $1,000
Q4 2020 Feb 02, 2021	BUY	$15.87 - $31.64 $4,126 - $8,226	260 Added 320.99%	341 $9,000
Q2 2020 Jul 16, 2020	SELL	$8.21 - $21.02 $3,439 - $8,807	-419 Reduced 83.8%	81 $1,000
Q1 2020 Apr 27, 2020	SELL	$7.81 - $18.82 $6,146 - $14,811	-787 Reduced 61.15%	500 $4,000
Q3 2019 Nov 01, 2019	BUY	$10.15 - $16.89 $10,160 - $16,906	1,001 Added 350.0%	1,287 $13,000
Q2 2019 Aug 05, 2019	BUY	$14.6 - $20.6 $4,175 - $5,891	286 New	286 $4,000
Q4 2018 Feb 05, 2019	SELL	$15.58 - $28.41 $3,193 - $5,824	-205 Closed	0 $0
Q1 2018 May 08, 2018	BUY	$27.78 - $35.19 $1,666 - $2,111	60 Added 41.38%	205 $6,000
Q3 2017 Nov 15, 2017	BUY	$21.65 - $32.18 $3,139 - $4,666	145 New	145 $3,000
Q3 2017 Nov 14, 2017	SELL	$21.65 - $32.18 $3,139 - $4,666	-145 Closed	0 $0
Q2 2017 Aug 07, 2017	BUY	N/A	145	145 $4,000

10.8M

5.9K

1.4K

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $71M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Parallel Advisors, LLC with notifications on news.